CA3049689A1 - Compositions and methods for augmenting antibody mediated receptor signaling - Google Patents

Compositions and methods for augmenting antibody mediated receptor signaling Download PDF

Info

Publication number
CA3049689A1
CA3049689A1 CA3049689A CA3049689A CA3049689A1 CA 3049689 A1 CA3049689 A1 CA 3049689A1 CA 3049689 A CA3049689 A CA 3049689A CA 3049689 A CA3049689 A CA 3049689A CA 3049689 A1 CA3049689 A1 CA 3049689A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
antibody
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3049689A
Other languages
English (en)
French (fr)
Inventor
Wayne A. Marasco
Quan Karen ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3049689A1 publication Critical patent/CA3049689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3049689A 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling Abandoned CA3049689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Publications (1)

Publication Number Publication Date
CA3049689A1 true CA3049689A1 (en) 2018-08-09

Family

ID=63040120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049689A Abandoned CA3049689A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Country Status (7)

Country Link
US (2) US20220213206A1 (https=)
EP (1) EP3576793A4 (https=)
JP (3) JP7231549B2 (https=)
CN (1) CN110520158A (https=)
AU (2) AU2018215673B2 (https=)
CA (1) CA3049689A1 (https=)
WO (1) WO2018145075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900500TA (en) * 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD4324851T2 (ro) 2018-07-19 2025-12-31 Regeneron Pharma Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JP6636803B2 (ja) * 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
AU2016227632A1 (en) 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
AU2016246695A1 (en) * 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
SG11201903693QA (en) * 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof

Also Published As

Publication number Publication date
AU2025202811A1 (en) 2025-05-08
US20240336694A1 (en) 2024-10-10
EP3576793A4 (en) 2021-03-31
JP2020505054A (ja) 2020-02-20
AU2018215673B2 (en) 2025-01-23
EP3576793A1 (en) 2019-12-11
CN110520158A (zh) 2019-11-29
JP2025028191A (ja) 2025-02-28
JP7231549B2 (ja) 2023-03-01
WO2018145075A1 (en) 2018-08-09
AU2025202811A9 (en) 2026-03-05
AU2018215673A1 (en) 2019-07-25
JP2023036899A (ja) 2023-03-14
US20220213206A1 (en) 2022-07-07
JP7606501B2 (ja) 2024-12-25

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
CN113286821B (zh) 靶向肿瘤的激动性cd28抗原结合分子
US20250066481A1 (en) Fc variant compositions and methods of use thereof
EP2760891B1 (en) Hybrid constant regions
WO2021198335A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
KR20250137191A (ko) D-도메인 함유 폴리펩타이드 및 이의 용도
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN106062206A (zh) 双特异性cd3和cd19抗原结合构建体
JP2022538718A (ja) 二重特異性抗体及びその調製方法、使用
US20240269176A1 (en) Heterodimeric fc domain antibodies
KR20230018425A (ko) 항-cd200r1 항체 및 이의 사용 방법
KR20250129817A (ko) D-도메인 함유 폴리펩티드 및 그의 용도
CN117715934A (zh) 抗cd3构建体及其用途
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220809